HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies.

Abstract
VEGF-A is important in tumor angiogenesis, and a humanized anti-VEGF-A monoclonal antibody (bevacizumab) has been approved by the FDA as a treatment for metastatic colorectal and nonsquamous, non-small-cell lung cancer in combination with chemotherapy. However, contributions of both tumor- and stromal-cell derived VEGF-A to vascularization of human tumors grown in immunodeficient mice hindered direct comparison between the pharmacological effects of anti-VEGF antibodies with different abilities to block host VEGF. Therefore, by gene replacement technology, we engineered mice to express a humanized form of VEGF-A (hum-X VEGF) that is recognized by many anti-VEGF antibodies and has biochemical and biological properties comparable with WT mouse and human VEGF-A. The hum-X VEGF mouse model was then used to compare the activity and safety of a panel of VEGF Mabs with different affinities for VEGF-A. Although in vitro studies clearly showed a correlation between binding affinity and potency at blocking endothelial cell proliferation stimulated by VEGF, in vivo experiments failed to document any consistent correlation between antibody affinity and the ability to inhibit tumor growth and angiogenesis in most animal models. However, higher-affinity antibodies were more likely to result in glomerulosclerosis during long-term treatment.
AuthorsHans-Peter Gerber, Xiumin Wu, Lanlan Yu, Christian Wiesmann, Xiao Huan Liang, Chingwei V Lee, Germaine Fuh, Christine Olsson, Lisa Damico, David Xie, Y Gloria Meng, Johnny Gutierrez, Racquel Corpuz, Bing Li, Linda Hall, Linda Rangell, Ron Ferrando, Henry Lowman, Franklin Peale, Napoleone Ferrara
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 104 Issue 9 Pg. 3478-83 (Feb 27 2007) ISSN: 0027-8424 [Print] United States
PMID17360669 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Recombinant Proteins
  • Vascular Endothelial Growth Factor A
Topics
  • Amino Acid Sequence
  • Animals
  • Antibodies, Monoclonal (metabolism, pharmacokinetics, pharmacology)
  • Antibody Affinity (genetics)
  • Carcinoma (metabolism)
  • Cell Proliferation (drug effects)
  • Humans
  • Kidney (drug effects, pathology)
  • Mice
  • Mice, Transgenic
  • Molecular Sequence Data
  • Mutagenesis
  • Neovascularization, Pathologic (metabolism)
  • Recombinant Proteins (metabolism)
  • Species Specificity
  • Vascular Endothelial Growth Factor A (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: